A Phase 2 interventional study of Mycophenolate Mofetil/Mycophenolic Acid and Obinutuzumab in Lupus Nephritis, sponsored by Hoffmann-La Roche. Completed at 46 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Nephritis by Hoffmann-La Roche — 2 open to participants now, 3 under way, 1 of them phase 3. Lupus Nephritis · Hoffmann-La Roche.
Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, this one is the 5th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 7th registered.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
Browse Lupus Nephritis studies →2 of the 11 studies in Lupus Nephritis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Argentina, Brazil, Colombia and 3 more countries
Ages 18+
Hoffmann-La Roche · Sites in United States, Brazil, Canada and 9 more countries
Ages 5–17
By country, each count listing its studies:
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 126 is above the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 52 across the 11 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
Drug: Mycophenolate Mofetil/Mycophenolic Acid · Drug: Obinutuzumab · Drug: Methylprednisolone · Drug: Prednisone
Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
Drug: Mycophenolate Mofetil/Mycophenolic Acid · Other: Placebo · Drug: Methylprednisolone · Drug: Prednisone
Drug page: Mycophenolic Acid
MMF/MPA will be administered as per schedule specified in the respective arm.
Obinutuzumab will be administered as per schedule specified in the respective arm.
Also known as: Gazyva, GA101, RO5072759
Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
Methylprednisolone IV will be administered as per schedule specified in the respective arm.
Prednisone will be administered as per schedule specified in the respective arm.
Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52
Percentage of participants with normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN range of central laboratory values.
Time frame: From baseline to Week 52
Percentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 52
OR includes both CRR and partial renal response (PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then urine protein:creatinine ratio of \<1.0. 2. If baseline protein:creatinine ratio is \> 3.0, then urine protein:creatinine ratio of \<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \<10 RBCs/HPF.
Time frame: From baseline to Week 52
Time to OR Over 52 Weeks
OR includes both CRR and partial renal response(PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in upcr, with one of these conditions met: 1. If baseline upcr is ≤3.0, then upcr of \<1.0. 2. If baseline pcr is \> 3.0, then upcr of \<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \<10 RBCs/HPF. Percentage of participants with response at various time points were measured using Kaplan Meier method.
Time frame: From baseline to Week 52
Percentage of Participants Who Achieve Protocol Defined Partial Renal Response (PRR) at Week 52
PRR defined as serum creatinine ≤15% above baseline value, no urinary red cell casts and either RBCs/HPF ≤ 50% above baseline or \< 10 RBCs/HPF, 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then a urine protein:creatinine ratio of \< 1.0. 2. If baseline protein:creatinine ratio is \> 3.0, then a urine protein:creatinine ratio of \< 3.0.
Time frame: Week 52
Percentage of Participants Who Achieve Protocol Defined CRR at Week 24
CRR defined as normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.
Time frame: Week 24
Time to CRR Over 52 Weeks
CRR included normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 RBCs/HPF and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the ULN range of central laboratory values if baseline serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values. Percentage of participants with response at various time points were measured using Kaplan Meier method.
Time frame: From Baseline to Week 52
Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody Levels at Week 52
Anti-dsDNA antibodies are a group of anti-nuclear autoantibodies targeting double stranded DNA.
Time frame: Baseline and Week 52
Change From Baseline in Complement Component 3 (C3) Levels at Week 52
Complement C3 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.
Time frame: Baseline and Week 52
Change From Baseline in C4 Levels at Week 52
Complement C4 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.
Time frame: Baseline, Week 52
Percentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 52
mCRR1 has got two components only, i.e. serum Creatinine and urinary protein to creatinine ratio. mCRR1 is defined by attainment of normalization of serum creatinine as evidenced by 1.) serum creatinine ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine ≤ the ULN range of central laboratory values and 2.) Urinary protein to creatinine ratio \<0.5.
Time frame: Week 52
Percentage of Participants Who Achieve Protocol Defined Second mCRR (mCRR2) at Week 52
mCRR2 is defined by normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 RBCs/HPF and the absence of red cell casts), and urinary protein to creatinine ratio \<0.5. Normalization of serum creatinine as evidenced by the following: Serum creatinine ≤15% above baseline if baseline (Day 1) serum creatinine is above the normal range of the central laboratory values or ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.
Time frame: Week 52
Percentage of Participants Who Achieve Protocol Defined Third mCRR (mCRR3) at Week 52
mCRR3 is defined by normalization of serum creatine as evidenced by serum creatinine ≤ the ULN range of central laboratory values and urinary protein to creatinine ratio \< 0.5.
Time frame: Week 52
Percentage of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs), Infections and Serious infections. The AEs reported do not include events after the receipt of rescue medications.
Time frame: From baseline to approximately 7 years and 8 months
Percentage of Participants With Adverse Events of Special Interest: Infusion Related Reactions, Grade 3 or Higher Infections, Drug-related Neutropenia and Drug-related Thrombocytopenia
Infusion related reaction is defined as any event reported within 24 hours of infusion and thought to be causally related to the investigational agent by the investigator. Grade 3 or higher infections include all events of Grade 3 to 5 under the SOC of infections and infestations. Drug-related neutropenia is defined as events in the Roche AE Grouped Term (AEGT) "Neutropenia and associated complications" and thought to be causally related to the investigational agent by the investigator. Drug-related thrombocytopenia is defined as events in the Standard MedDRA Query (SMQ) "Haematopoietic Thrombocytopenia narrow" and thought to be causally related to the investigational agent by the investigator.
Time frame: From baseline to approximately 7 years and 8 months
Percentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab
Antibodies are a blood protein produced in response to and counteracting a specific antigen.
Time frame: From baseline to approximately 7 years and 8 months
Percent Change From Baseline in Circulating CD19-Positive B-Cell Levels
CD19+ B cell is a B-lymphocyte with a transmembrane protein that is encoded by the gene CD19.
Time frame: Baseline, Week 2, Week 4, Week 12, Week 24, Week 52, Week 104, B Cell Follow-Up (Bcfu) at months 6, 12, 18, 24, 30, 36, 42 and 48
Maximum Observed Plasma Concentration (Cmax) of Obinutuzumab
Time frame: Week 0, Week 24, Week 52
Area Under the Plasma Concentration Versus Time Curve (AUC) of Obinutuzumab
Time frame: Baseline to Week 52
Systemic Clearance of Obinutuzumab
Time frame: Day 0, Week 24, Week 52
Volume of Distribution Under Steady State (Vss) of Obinutuzumab
Time frame: Day 0, Week 24, Week 52
Terminal Plasma Half-Life (t1/2) of Obinutuzumab
Time frame: Day 0, Week 24, Week 52
Change From Baseline of Participant's Global Assessment of Disease Activity Visual Analog Scale (VAS) Score
Each VAS had a range from 0-100 with higher scores indicating greater symptom impact on global health status.
Time frame: Baseline (Day 1), Weeks 4, 12, 24, 36, 52
| Milestone | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Started | 63 | 62 |
| Completed | 55 | 44 |
| Not completed | 8 | 18 |
| Withdrew: Death | 1 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 |
| Withdrew: Post trial access | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Receipt of additional therapies that reduce peripheral b cell counts | 0 | 2 |
Percentage of participants with normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN range of central laboratory values.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52 | 22 | 14 |
OR includes both CRR and partial renal response (PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then urine protein:creatinine ratio of \<1.0. 2. If baseline protein:creatinine ratio is \> 3.0, then urine protein:creatinine ratio of \<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \<10 RBCs/HPF.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Percentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 52 | 35 | 22 |
OR includes both CRR and partial renal response(PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in upcr, with one of these conditions met: 1. If baseline upcr is ≤3.0, then upcr of \<1.0. 2. If baseline pcr is \> 3.0, then upcr of \<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \<10 RBCs/HPF. Percentage of participants with response at various time points were measured using Kaplan Meier method.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Week 12 | 55 | 59 |
| Week 24 | 33 | 37 |
| Week 36 | 21 | 29 |
| Week 52 | 14 | 21 |
PRR defined as serum creatinine ≤15% above baseline value, no urinary red cell casts and either RBCs/HPF ≤ 50% above baseline or \< 10 RBCs/HPF, 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then a urine protein:creatinine ratio of \< 1.0. 2. If baseline protein:creatinine ratio is \> 3.0, then a urine protein:creatinine ratio of \< 3.0.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Percentage of Participants Who Achieve Protocol Defined Partial Renal Response (PRR) at Week 52 | 35 | 21 |
CRR defined as normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Percentage of Participants Who Achieve Protocol Defined CRR at Week 24 | 16 | 17 |
CRR included normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 RBCs/HPF and the absence of red cell casts) and urinary protein to creatinine ratio \< 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the ULN range of central laboratory values if baseline serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values. Percentage of participants with response at various time points were measured using Kaplan Meier method.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Week 12 | 61 | 60 |
| Week 24 | 47 | 48 |
| Week 36 | 38 | 38 |
| Week 52 | 27 | 33 |
Anti-dsDNA antibodies are a group of anti-nuclear autoantibodies targeting double stranded DNA.
| log IU/mL | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody Levels at Week 52 | -0.810 ± 1.054 | -0.076 ± 1.103 |
Complement C3 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.
| g/L | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Change From Baseline in Complement Component 3 (C3) Levels at Week 52 | 0.311 ± 0.302 | 0.106 ± 0.273 |
Complement C4 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.
| g/L | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Change From Baseline in C4 Levels at Week 52 | 0.101 ± 0.117 | 0.004 ± 0.164 |
mCRR1 has got two components only, i.e. serum Creatinine and urinary protein to creatinine ratio. mCRR1 is defined by attainment of normalization of serum creatinine as evidenced by 1.) serum creatinine ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine ≤ the ULN range of central laboratory values and 2.) Urinary protein to creatinine ratio \<0.5.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Percentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 52 | 25 | 16 |
mCRR2 is defined by normalization of serum creatinine, inactive urinary sediment (as evidenced by \< 10 RBCs/HPF and the absence of red cell casts), and urinary protein to creatinine ratio \<0.5. Normalization of serum creatinine as evidenced by the following: Serum creatinine ≤15% above baseline if baseline (Day 1) serum creatinine is above the normal range of the central laboratory values or ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Percentage of Participants Who Achieve Protocol Defined Second mCRR (mCRR2) at Week 52 | 28 | 21 |
mCRR3 is defined by normalization of serum creatine as evidenced by serum creatinine ≤ the ULN range of central laboratory values and urinary protein to creatinine ratio \< 0.5.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Percentage of Participants Who Achieve Protocol Defined Third mCRR (mCRR3) at Week 52 | 29 | 24 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs), Infections and Serious infections. The AEs reported do not include events after the receipt of rescue medications.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Adverse Events | 58 | 54 |
| Grade 3 AEs | 19 | 15 |
| Grade 4 AEs | 6 | 7 |
| Grade 5 AEs | 1 | 2 |
| Serious Adverse Events | 16 | 17 |
| Infections | 48 | 38 |
| Serious infections | 5 | 10 |
Infusion related reaction is defined as any event reported within 24 hours of infusion and thought to be causally related to the investigational agent by the investigator. Grade 3 or higher infections include all events of Grade 3 to 5 under the SOC of infections and infestations. Drug-related neutropenia is defined as events in the Roche AE Grouped Term (AEGT) "Neutropenia and associated complications" and thought to be causally related to the investigational agent by the investigator. Drug-related thrombocytopenia is defined as events in the Standard MedDRA Query (SMQ) "Haematopoietic Thrombocytopenia narrow" and thought to be causally related to the investigational agent by the investigator.
| Participants | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Infusion Related Reactions | 10 | 6 |
| Grade 3 or Higher Infections | 4 | 11 |
| Drug-related Neutropenia | 3 | 2 |
| Drug-related Thrombocytopenia | 0 | 0 |
Antibodies are a blood protein produced in response to and counteracting a specific antigen.
| Participants | OBINUTUZUMAB 1000MG and MMF |
|---|---|
| Percentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab | 7 |
CD19+ B cell is a B-lymphocyte with a transmembrane protein that is encoded by the gene CD19.
| Percent change of cells/uL | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Week 2 | -97.469 ± 12.899 | 39.293 ± 145.247 |
| Week 4 | -98.777 ± 5.235 | -5.186 ± 78.469 |
| Week 12 | -97.045 ± 15.506 | 0.661 ± 134.421 |
| Week 24 | -96.628 ± 10.207 | -11.446 ± 86.793 |
| Week 52 | -98.620 ± 5.677 | 37.695 ± 220.857 |
| Week 104 | 77.123 ± 380.111 | -76.055 ± 31.519 |
| Bcfu Month 6 | 105.043 ± 402.281 | -73.889 ± 19.755 |
| Bcfu Month 12 | 77.123 ± 380.111 | -76.055 ± 31.519 |
| Bcfu Month 18 | -83.159 ± 16.701 | -11.418 ± NA |
| Bcfu Month 24 | -93.603 ± 8.836 | — |
| Bcfu Month 30 | -59.950 ± 50.807 | — |
| Bcfu Month 36 | -99.163 ± 0.973 | — |
| Bcfu Month 42 | -99.084 ± NA | — |
| Bcfu Month 48 | -99.851 ± NA | — |
| ug/mL | OBINUTUZUMAB 1000MG and MMF |
|---|---|
| Week 0-24 | 559 ± 112 |
| Week 24-52 | 605 ± 115 |
| Week 0-52 | 605 ± 115 |
| ug/mL*day | OBINUTUZUMAB 1000MG and MMF |
|---|---|
| Week 0-24 | 10595 ± 4016 |
| Week 24-52 | 15811 ± 5543 |
| Week 0-52 | 26406 ± 9027 |
| L/day | OBINUTUZUMAB 1000MG and MMF |
|---|---|
| Day 0 | 0.255 ± 0.136 |
| Week 24 | 0.147 ± 0.0564 |
| Week 52 | 0.137 ± 0.0535 |
| Litre (L) | OBINUTUZUMAB 1000MG and MMF |
|---|---|
| Day 0 | 3.67 ± 0.591 |
| Week 24 | 3.67 ± 0.591 |
| Week 52 | 3.67 ± 0.591 |
| day | OBINUTUZUMAB 1000MG and MMF |
|---|---|
| Day 0 | 13.1 ± 3.7 |
| Week 24 | 20.5 ± 5.6 |
| Week 52 | 22.1 ± 6.7 |
Each VAS had a range from 0-100 with higher scores indicating greater symptom impact on global health status.
| score on scale | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF |
|---|---|---|
| Baseline | 41.3 ± 25.59 | 39.4 ± 24.76 |
| Week 4 | -14.4 ± 18.28 | -8.7 ± 22.69 |
| Week 12 | -19.9 ± 25.07 | -11.6 ± 25.22 |
| Week 24 | -25.0 ± 25.17 | -20.8 ± 24.74 |
| Week 36 | -24.8 ± 25.71 | -19.6 ± 25.04 |
| Week 52 | -25.4 ± 26.49 | -23.3 ± 25.76 |
Collected over From baseline to approximately 7 years and 8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OBINUTUZUMAB 1000MG + MMF | 1/64 (1.6%) | 17/64 (26.6%) | 51/64 (79.7%) |
| PLACEBO + MMF | 4/61 (6.6%) | 18/61 (29.5%) | 39/61 (63.9%) |
| Event | OBINUTUZUMAB 1000MG + MMF | PLACEBO + MMF |
|---|---|---|
| HERPES ZOSTERInfections and infestations | 1/64 | 3/61 |
| SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders | 2/64 | 2/61 |
| RENAL FAILURERenal and urinary disorders | 0/64 | 2/61 |
| PYREXIAGeneral disorders | 2/64 | 1/61 |
| ABDOMINAL PAINGastrointestinal disorders | 2/64 | 0/61 |
| NEUTROPENIABlood and lymphatic system disorders | 1/64 | 1/61 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/64 | 1/61 |
| CARDIAC FAILURECardiac disorders | 0/64 | 1/61 |
| INTESTINAL PERFORATIONGastrointestinal disorders | 0/64 | 1/61 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 0/64 | 1/61 |
| Event | OBINUTUZUMAB 1000MG + MMF | PLACEBO + MMF |
|---|---|---|
| URINARY TRACT INFECTIONInfections and infestations | 14/64 | 12/61 |
| BRONCHITISInfections and infestations | 13/64 | 5/61 |
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 7/64 | 6/61 |
| GASTROENTERITISInfections and infestations | 3/64 | 6/61 |
| HERPES ZOSTERInfections and infestations | 5/64 | 6/61 |
| NASOPHARYNGITISInfections and infestations | 5/64 | 6/61 |
| NAUSEAGastrointestinal disorders | 6/64 | 3/61 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 6/64 | 5/61 |
| HYPERTENSIONVascular disorders | 6/64 | 2/61 |
| DIARRHOEAGastrointestinal disorders | 3/64 | 5/61 |
| Age, Continuous(Years) | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF | Total |
|---|---|---|---|
| Mean | 33.1 ± 9.8 | 31.9 ± 10.1 | 32.5 ± 9.9 |
| Sex: Female, Male(Participants) | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF | Total |
|---|---|---|---|
| Female | 55 | 51 | 106 |
| Male | 8 | 11 | 19 |
| Race/Ethnicity, Customized(Participants) | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF | Total |
|---|---|---|---|
| Hispanic Or Latino | 42 | 49 | 91 |
| Not Hispanic Or Latino | 20 | 12 | 32 |
| Not Stated | 1 | 0 | 1 |
| Unknown | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 17 | 28 |
| Asian | 3 | 2 | 5 |
| Black or African American | 6 | 5 | 11 |
| Multiple | 1 | 0 | 1 |
| Native Hawaiian or other Pacific Islande | 1 | 0 | 1 |
| Unknown | 13 | 12 | 25 |
| White | 28 | 26 | 54 |
| Circulating CD19-Positive B-Cell Levels(cells/uL) | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF | Total |
|---|---|---|---|
| Mean | 328 ± 331 | 353 ± 454 | 341 ± 395 |
| Region of Enrollment(Participants) | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF | Total |
|---|---|---|---|
| Asia | 2 | 2 | 4 |
| European Union | 16 | 5 | 21 |
| Latin America | 37 | 46 | 83 |
| United States | 7 | 8 | 15 |
| Lupus Nephritis (LN) Biopsy Class(Participants) | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF | Total |
|---|---|---|---|
| III | 14 | 17 | 31 |
| IV | 49 | 45 | 94 |
| Urine Protein Creatinine Ratio (UPCR)(mg/mg) | OBINUTUZUMAB 1000MG and MMF | PLACEBO and MMF | Total |
|---|---|---|---|
| Mean | 3.32 ± 2.66 | 2.93 ± 2.46 | 3.12 ± 2.56 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Nov 2015 to primary completion in Jan 2019, 38 months.
Results were first posted in Feb 2020, 1 year 1 month after primary completion.
Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab